Chengdu Bright Eye Hospital Co. Ltd. Total Liabilities
Chengdu Bright Eye Hospital Co. Ltd. total liabilities. Based on the latest financial reports, Chengdu Bright Eye Hospital Co. Ltd. (301239) has total liabilities worth CN¥2.60 Billion CNY (≈ $380.94 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Chengdu Bright Eye Hospital Co. Ltd. (301239) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Chengdu Bright Eye Hospital Co. Ltd. (2019–2025)
Total liabilities of Chengdu Bright Eye Hospital Co. Ltd. from 2019 to 2025. This chart illustrates how Chengdu Bright Eye Hospital Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data.
Chengdu Bright Eye Hospital Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Chengdu Bright Eye Hospital Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Link Mobility Group Holding ASA
OL:LINK
|
Norway | Nkr5.22 Billion |
|
Aces Electronics Co Ltd
TW:3605
|
Taiwan | NT$6.76 Billion |
|
LianChuang Electronic Technology Co Ltd
SHE:002036
|
China | CN¥15.41 Billion |
|
Cantaloupe Inc
NASDAQ:CTLP
|
USA | $126.77 Million |
|
Baota Industry Co Ltd
SHE:000595
|
China | CN¥9.27 Billion |
|
Suzhou Hycan Holdings Co Ltd
SHE:002787
|
China | CN¥1.13 Billion |
|
Greencoat Renewables PLC
IR:GRP
|
Ireland | €1.28 Billion |
|
Varex Imaging Corp
NASDAQ:VREX
|
USA | $589.50 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Chengdu Bright Eye Hospital Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Chengdu Bright Eye Hospital Co. Ltd. asset portfolio.
Liquidity & Leverage Metrics
Chengdu Bright Eye Hospital Co. Ltd. Total Liabilities Ratios Explained
Chengdu Bright Eye Hospital Co. Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Bright Eye Hospital Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Bright Eye Hospital Co. Ltd. (2019–2025)
The table below shows the annual total liabilities of Chengdu Bright Eye Hospital Co. Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.49 Billion ≈ $364.19 Million |
+0.48% |
| 2024-12-31 | CN¥2.48 Billion ≈ $362.44 Million |
-0.80% |
| 2023-12-31 | CN¥2.50 Billion ≈ $365.36 Million |
+55.13% |
| 2022-12-31 | CN¥1.61 Billion ≈ $235.51 Million |
+16.85% |
| 2021-12-31 | CN¥1.38 Billion ≈ $201.55 Million |
+12.60% |
| 2020-12-31 | CN¥1.22 Billion ≈ $178.99 Million |
+425.20% |
| 2019-12-31 | CN¥232.90 Million ≈ $34.08 Million |
-- |
About Chengdu Bright Eye Hospital Co. Ltd.
Bright Eye Hospital Group Co., Ltd., together with its subsidiaries, operates ophthalmic medical institutions in China. The company offers ophthalmic diagnostic and treatment services, including refractive surgery, medical optometry and glasses fitting, cataract surgery, glaucoma treatment, strabismus and amblyopia, pediatric ophthalmology, fundus diseases treatment, oculoplastic surgery, lacrima… Read more